MitraClip: Impact of Sinus Rhythm and Heart Rate

MitraClip: Impact of Sinus Rhythm and Heart RateCourtesy of Dr. Carlos Fava.

Atrial fibrillation (AF) and fast heart rate (>70 lpm) have been shown to increase the risk of mitral valve repair surgery. The MitraClip has shown benefits in high risk patients, but its relation to abnormal heart rhythm has not yet been established.

 

760 patients were analyzed; 315 (52.4%) presented sinus rhythm (SR) and 286 (47.6%) atrial fibrillation. In the SR group, 365 patients (46.8%) presented a ≤70 lpm heart rate, and 404 (53.2%), a >70 lpm heart rate.

 

AF patients were older, had mild ventricular deterioration, and larger left auricular diameter. On the other hand, SR patients more often presented a history of MI, diabetes, (especially those with <70 heart rate), severe left ventricular function deterioration and increased end-diastolic volume.

 

Procedural success was 97.5%, with no significant differences between subgroups as regards:

  • procedural time
  • fluoroscopy
  • number of clips implanted
  • intra-procedural complications

 

There were no differences as regards in hospital stay, though SR patients presenting <70 lpm heart rate saw a shorter stay.

 

At 30 days, there were no differences in mortality (SR 3%, AF 5.8%, SR≤70 4.3% and SR>70 4.5%). The only mortality predictor was a >2 mg/dl creatinine value. Functional class saw sustained improvement across all subgroups.

 

Conclusion

These registry data (comparing a large “real world” unselected series of patients with mitral regurgitation receiving MitraClip) suggest that this intervention is safe and effective and that it reduces mitral regurgitation in most patients, regardless of baseline sinus rhythm or heart rate. While at 12 months survival rate was higher for those in SR, MACE and clinical improvement was no different between the groups.

 

Editorial Comment

This analysis of the German registry shows the MitraClip has benefits for high risk patients regardless of sinus rhythm or heart rate, as opposed to mitral valve surgery.

 

It is important to intervene before kidney failure, since this has a negative impact on results.

 

We need to evaluate these outcomes against those of larger studies.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

Original Title: Effects of atrial fibrillation and heart rateo in percutaneous mitral valve repair with MitraClip: results from the TRAnscatheter Mitral valve Intervention (TRAMI) registry.

Reference: Alexnader Jabs et al. EuroIntervention 2017;12:1697-1705.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...